Pharmaceutical Monopoly Rights and Ridiculously High Prices

A recent study published in the Journal of the American Medical Association (JAMA) blamed market exclusivity or monopoly rights for the high per capita drug spending in the U.S. and ridiculously high prices. Read more here. (Source: Arlene Weintraub, Forbes, 9/1/16)

You might also be interested in:

Laws Targeting Cancer Drug Costs Falling Short November 13, 2017
Thrusting More Value into Biopharma Assessments January 4, 2018
JAMA Article Takes Look at Value-Based Drug Pricing June 6, 2018
Regeneron Takes Fight to Drug Pricing System July 28, 2018
Physician Pay Pushes 257K Annually; $425K for Specialist Pay May 27, 2018
Report: Doctors’ Salaries, Drug Prices Main Driver of… March 15, 2018
25 Countries Top U.S. in Life Expectancy September 27, 2018